SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Emary, KRW; Golubchik, T; Aley, PK; Ariani, CV; Angus, B; Bibi, S; Blane, B; Bonsall, D; Cicconi, P; Charlton, S; et al. Emary, KRW; Golubchik, T; Aley, PK; Ariani, CV; Angus, B; Bibi, S; Blane, B; Bonsall, D; Cicconi, P; Charlton, S; Clutterbuck, EA; Collins, AM; Cox, T; Darton, TC; Dold, C; Douglas, AD; Duncan, CJA; Ewer, KJ; Flaxman, AL; Faust, SN; Ferreira, DM; Feng, S; Finn, A; Folegatti, PM; Fuskova, M; Galiza, E; Goodman, AL; Green, CM; Green, CA; Greenland, M; Hallis, B; Heath, PT; Hay, J; Hill, HC; Jenkin, D; Kerridge, S; Lazarus, R; Libri, V; Lillie, PJ; Ludden, C; Marchevsky, NG; Minassian, AM; McGregor, AC; Mujadidi, YF; Phillips, DJ; Plested, E; Pollock, KM; Robinson, H; Smith, A; Song, R; Snape, MD; Sutherland, RK; Thomson, EC; Toshner, M; Turner, DPJ; Vekemans, J; Villafana, TL; Williams, CJ; Hill, AVS; Lambe, T; Gilbert, SC; Voysey, M; Ramasamy, MN; Pollard, AJ; COVID-19 Genomics UK consortium; AMPHEUS Project; Oxford COVID-19 Vaccine Trial Group (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, 397 (10282). pp. 1351-1362. ISSN 1474-547X https://doi.org/10.1016/S0140-6736(21)00628-0
SGUL Authors: Heath, Paul Trafford

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
[img]
Preview
PDF (Supplementary appendix) Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

BACKGROUND: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. METHODS: Volunteers (aged ≥18 years) who were enrolled in phase 2/3 vaccine efficacy studies in the UK, and who were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control (MenACWY) vaccine, provided upper airway swabs on a weekly basis and also if they developed symptoms of COVID-19 disease (a cough, a fever of 37·8°C or higher, shortness of breath, anosmia, or ageusia). Swabs were tested by nucleic acid amplification test (NAAT) for SARS-CoV-2 and positive samples were sequenced through the COVID-19 Genomics UK consortium. Neutralising antibody responses were measured using a live-virus microneutralisation assay against the B.1.1.7 lineage and a canonical non-B.1.1.7 lineage (Victoria). The efficacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to vaccine received. Vaccine efficacy was calculated as 1 - relative risk (ChAdOx1 nCoV-19 vs MenACWY groups) derived from a robust Poisson regression model. This study is continuing and is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137. FINDINGS: Participants in efficacy cohorts were recruited between May 31 and Nov 13, 2020, and received booster doses between Aug 3 and Dec 30, 2020. Of 8534 participants in the primary efficacy cohort, 6636 (78%) were aged 18-55 years and 5065 (59%) were female. Between Oct 1, 2020, and Jan 14, 2021, 520 participants developed SARS-CoV-2 infection. 1466 NAAT positive nose and throat swabs were collected from these participants during the trial. Of these, 401 swabs from 311 participants were successfully sequenced. Laboratory virus neutralisation activity by vaccine-induced antibodies was lower against the B.1.1.7 variant than against the Victoria lineage (geometric mean ratio 8·9, 95% CI 7·2-11·0). Clinical vaccine efficacy against symptomatic NAAT positive infection was 70·4% (95% CI 43·6-84·5) for B.1.1.7 and 81·5% (67·9-89·4) for non-B.1.1.7 lineages. INTERPRETATION: ChAdOx1 nCoV-19 showed reduced neutralisation activity against the B.1.1.7 variant compared with a non-B.1.1.7 variant in vitro, but the vaccine showed efficacy against the B.1.1.7 variant of SARS-CoV-2. FUNDING: UK Research and Innovation, National Institute for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, and AstraZeneca.

Item Type: Article
Additional Information: © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Keywords: COVID-19 Genomics UK consortium, AMPHEUS Project, Oxford COVID-19 Vaccine Trial Group, General & Internal Medicine, 11 Medical and Health Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Lancet
ISSN: 1474-547X
Language: eng
Dates:
DateEvent
10 April 2021Published
30 March 2021Published Online
10 March 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
203141/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
MC_PC_19055Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
EP/R013756/1Engineering and Physical Sciences Research Councilhttp://dx.doi.org/10.13039/501100000266
001Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorhttp://dx.doi.org/10.13039/501100002322
2018-I2M-2–002Chinese Academy of Medical SciencesUNSPECIFIED
PubMed ID: 33798499
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113167
Publisher's version: https://doi.org/10.1016/S0140-6736(21)00628-0

Actions (login required)

Edit Item Edit Item